Advertising disclosure: we may earn a commission when you buy through links on this site. How we make money

HomeTrials › NCT06859268

Obesity & weight · Phase 3 · Active, not recruiting

A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity

NCT06859268 · Sponsor: Eli Lilly and Company

What this trial means for you

This study is active, not recruiting — it is not currently taking new participants, but its results may matter for treatments you're considering. It's studying Retatrutide, Placebo for obesity.

Who can joinAll sexes, 18 Years and older
Healthy volunteersNo — diagnosis required
What you'd takeRetatrutide, Placebo
Study length~3.1 years overall
Planned participants643
TypeInterventional (you receive treatment)

What participants typically get: study medication (or placebo, if the trial uses one) and study-related medical care at no cost, plus close monitoring. Compensation for time and travel varies by study — ask the site. Note that in many trials you can't choose your treatment group, and some participants receive a placebo.

The study, in the sponsor's words

This is a study of retatrutide in participants with obesity. The main purpose is to learn more about how retatrutide maintains body weight loss. The study will have two treatment phases: an 80 week lead-in phase in which all participants will take retatrutide dose 1 and a 36 week randomized, double-blinded phase in which participants will either take retatrutide dose 1, retatrutide dose 2, or switch to placebo. Participation in the study will last around 125 weeks.

Can you join? The exact criteria

Below is the verbatim eligibility text from the registry — bring it to your doctor; it's written for clinicians, and your own clinician is the right person to interpret it with you.

Full eligibility criteria (for you and your doctor)

Inclusion Criteria: * Have obesity and a history of at least one self-reported unsuccessful dietary effort to reduce body weight Exclusion Criteria: * Have a self-reported change in body weight \>5 kilograms (kg) (11 pounds) within 90 days before screening * Have a prior or planned surgical treatment for obesity * Have a prior or planned endoscopic procedure and/or device-based therapy for obesity * Have Type 1 Diabetes, Type 2 Diabetes, or any other type of diabetes * Have a family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2) * Have had within the past 90 days before screening: * acute myocardial infarction * cerebrovascular accident (stroke) * hospitalization for unstable angina, or * hospitalization due to congestive heart failure * Have New York Heart Association Functional Classification Class IV congestive heart failure * Have a history of chronic or acute pancreatitis * Have taken weight loss drugs, including over-the-counter medications, within 90 days prior to screening

Study sites by state

California

  • Southern California Clinical Research — Santa Ana

Colorado

  • University of Colorado Anschutz Medical Campus — Aurora

Connecticut

  • CMR of Greater New Haven, LLC — Hamden

Florida

  • ALL Medical Research, LLC — Cooper City
  • Florida International Medical Research — Coral Gables
  • Renstar Medical Research — Ocala
  • Charter Research - Winter Park — Orlando
  • Metabolic Research Institute, Inc. — West Palm Beach

Georgia

  • Kubost Clinical Research - Marietta — Marietta
  • North Georgia Clinical Research — Woodstock

Hawaii

  • Pacific Diabetes & Endocrine Center — Honolulu

Illinois

  • Alliance for Multispecialty Research, LLC — Oak Brook
  • Springfield Clinic Main Campus — Springfield

Kentucky

  • Alliance for Multispecialty Research, LLC — Lexington
  • L-MARC Research Center — Louisville

Louisiana

  • Pennington Biomedical Research Center — Baton Rouge
  • Care Access - Lake Charles (Bayou Pines) — Lake Charles

Massachusetts

  • Massachusetts General Hospital — Boston

Missouri

  • Alliance for Multispecialty Research, LLC — Kansas City

Nevada

  • Vector Clinical Trials — Las Vegas

New York

  • Dent Neurosciences Research Center, Inc — Amherst

North Carolina

  • Carteret Medical Group — Morehead City
  • Care Access - Raleigh — Raleigh

Oklahoma

  • Tekton Research, LLC. — Moore

Pennsylvania

  • Altoona Center For Clinical Research — Duncansville

South Dakota

  • Care Access - Rapid City — Rapid City

Tennessee

  • Alliance for Multispecialty Research, LLC — Knoxville

Texas

  • Care Access - Houston — Houston
  • Southern Endocrinology Associates — Mesquite
  • Sleep Therapy Research Center — San Antonio

Virginia

  • National Clinical Research, Inc — Richmond

Washington

  • Northwest Clinical Research Center — Bellevue
  • Central Washington Health Services Association d/b/a Confluence Health — Wenatchee

View the official record on ClinicalTrials.gov →

Verify before you act. Medical disclaimer: content on this site is for informational purposes only and is not medical advice. GLP-1 medications are prescription drugs; always consult a licensed healthcare provider about eligibility, risks, and benefits. Trial details and enrollment status change frequently — always verify on the official registry and talk to your own clinician before contacting a study site. This page was generated from registry data and is not affiliated with the study sponsor.

Follow this trial

Get an email when our monthly digest covers enrollment changes and results for trials like this one.

Newsletter signup launches soon. (Site owner: set PUBLIC_BUTTONDOWN_USERNAME in .env to activate this form.)

Keep researching on StudyBackedHealth